Versão HTML básica
377
Chronic myeloid leukemia treatment guidelines: Brazilian Association of Hematology, Hemotherapy and Cell Therapy. Brazilian Medical Association Guidelines Project – 2012
Rev Bras Hematol Hemoter. 2012;34(5):367-82
myeloid leukemia are correlated with Sokal risk scores and duration of
therapy but not trough imatinib plasma levels. Leuk Res 2009;33(2):271-5.
Comment in: Leuk Res. 2009;33(8):1147-8; author reply 1149-50.
38. Hasford J, Pfirrmann M, Hehlmann R, Baccarani M, Guilhot F,
Mahon FX, Kluin-Nelemans HC, Ohnishi K, Thaler J, Steegmann
JL; Collaborative CML Prognostic Factors Project Group. Prognosis
and prognostic factors for patients with chronic myeloid leukemia:
nontransplant therapy. Semin Hematol. 2003;40(1):4-12.
39. Rajappa S, Varadpande L, Paul T, Jacob R, Digumarti R. Imatinib
mesylate in early chronic phase chronic myeloid leukemia: Experience
from a developing country. Leuk Lymphoma. 2008;49(3):554-8.
40. Lee JP, Birnstein E, Masiello D, Yang D, Yang AS. Gender and ethnic
differences in chronic myelogenous leukemia prognosis and treatment
response: a single-institution retrospective study. J Hematol Oncol. 2009;2:30.
41. Kantarjian H, Shah NP, Hochhaus A, Cortes J, Shah S, Ayala M, et al.
Dasatinib versus imatinib in newly diagnosed chronic-phase chronic
myeloid leukemia. N Engl J Med. 2010;362(24):2260-70. Comment in:
N Engl J Med
.
2010
;
362
(24):2314-5.
N Engl J Med
. 2010
;363(17):1672-
3; author reply 1673-5
.
Expert Opin Pharmacother
. 2011;12(1):157-63.
N Engl J Med. 2010;363(17):1673;author reply 1673-5.
42. Kantarjian HM, Shah NP, Cortes JE, Baccarani M, Agarwal MB,
Undurraga MS, et al. Dasatinib or imatinib in newly diagnosed chronic-
phase chronic myeloid leukemia: 2 year follow-up from a randomized
phase 3 trial (DASISION). Blood. 2012;119(5):1123-9.
43. Saglio G, KimDW, Issaragrisil S, le Coutre P, Etienne G, Lobo C, Pasquini
R, Clark RE, Hochhaus A, Hughes TP, Gallagher N, Hoenekopp A, Dong
M, HaqueA, Larson RA, Kantarjian HM+ Collaborators (223); ENESTnd
Investigators. Nilotinib versus imatinib for newly diagnosed chronic
myeloid leukemia. N Engl J Med. 2010;362(24):2251-9. Comment in: N
Engl J Med
.
2010
;362(24):2314-5;
N Engl J Med
.
2010
;
363(17):1672;
author reply 1673-5; Expert Opin Pharmacother. 2011;12(1):157-63; N
Engl J Med. 2010
;
363(17):1673; author reply 1673-5.
44. Kantarjian HM, Hochhaus A, Saglio G, De Souza C, Flinn IW, Stenke
L, et al. Nilotinib versus imatinib for the treatment of patients with
newly diagnosed chronic phase, Philadelphia chromosome-positive,
chronic myeloid leukaemia: 24-month minimum follow-up of the
phase 3 randomised ENESTnd trial. Lancet Oncol. 2011;12(9):841-51.
Comment in: Lancet Oncol. 2011;12(9):826-7.
45. Breccia M, Stefanizzi C, Cannella L, Latagliata R, Frustaci AM,
Carmosino I, et al. Differences in hematological and non-hematological
toxicity during treatment with imatinib in patients with early and
late chronic phase chronic myeloid leukemia. Leuk Lymphoma.
2008;49(12):2328-32.
46. Scerni AC, Alvares LA, Beltrão AC, Bentes IR, Azevedo TC, Bentes
AQ, et al. Influence of late treatment on how chronic myeloid leukemia
responds to imatinib. Clinics (Sao Paulo). 2009;64(8):731-4.
47. Cortes JE, Talpaz M, Giles F, O’Brien S, Rios MB, Shan J, et al.
Prognostic significance of cytogenetic clonal evolution in patients with
chronic myelogenous leukemia on imatinib mesylate therapy. Blood.
2003;101(10):3794-800.
48. Kantarjian HM, Cortes JE, O’Brien S, Luthra R, Giles F, Verstovsek
S, et al. Long-term survival benefit and improved complete cytogenetic
and molecular response rates with imatinib mesylate in Philadelphia
chromosome-positive chronic-phase chronic myeloid leukemia after
failure of interferon-alpha. Blood. 2004;104(7):1979-88.
49. Palandri F, Iacobucci I, Martinelli G, Amabile M, Poerio A, Testoni N,
Soverini S, Castagnetti F, De Vivo A, Breccia M, Specchia G, Abruzzese
E, Martino B, Cilloni D, Saglio G, Pane F, Liberati AM, Rosti G,
Baccarani M; GIMEMA Working Party on CML. Long-term outcome
of complete cytogenetic responders after imatinib 400 mg in late chronic
phase, philadelphia-positive chronic myeloid leukemia: the GIMEMA
Working Party on CML. J Clin Oncol. 2008;26(1):106-11.
50. Gambacorti-Passerini C, Antolini L, Mahon FX, Guilhot F, Deininger
M, Fava C, et al. Multicenter independent assessment of outcomes
in chronic myeloid leukemia patients treated with imatinib. J Natl
Cancer Inst. 2011;103(7):553-61. Comment in: J Natl Cancer Inst.
2011;103(7):527-9.
51. Fava C, Kantarjian HM, Jabbour E, O’Brien S, Jain N, Rios MB, et al.
Failure to achieve a complete hematologic response at the time of a major
cytogenetic response with second-generation tyrosine kinase inhibitors
is associated with a poor prognosis among patients with chronic myeloid
leukemia in accelerated or blast phase. Blood. 2009;113(21):5058-63.
52. Milojkovic D, Nicholson E, Apperley JF, Holyoake TL, Shepherd P,
Drummond MW, et al. Early prediction of success or failure of treatment
with second-generation tyrosine kinase inhibitors in patients with
chronic myeloid leukemia. Haematologica. 2010;95(2):224-31.
53. Marin D, Kaeda J, Szydlo R, Saunders S, Fleming A, Howard J, et al.
Monitoring patients in complete cytogenetic remission after treatment of
CML in chronic phase with imatinib: patterns of residual leukaemia and
prognostic factors for cytogenetic relapse. Leukemia. 2005;19(4):507-12.
54. Furukawa T, Narita M, Koike T, Takai K, Nagai K, Kobayashi M,
Koyama S, et al. Clinical value of assessing the response to imatinib
monitored by interphase FISH and RQ-PCR for BCR-ABL in peripheral
blood for long-term survival of chronic phase CML patients: results of
the Niigata CML-multi-institutional co-operative clinical study. Int J
Hematol. 2011;93(3):336-43.
55. Cortes JE, Kantarjian HM, Goldberg SL, Powell BL, Giles FJ, Wetzler
M, Akard L, Burke JM, Kerr R, Saleh M, Salvado A, McDougall K,
Albitar M, Radich J; Rationale and Insight for Gleevec High-Dose
Therapy (RIGHT) Trial Study Group. High-dose imatinib in newly
diagnosed chronic-phase chronic myeloid leukemia: high rates of rapid
cytogenetic and molecular responses. J Clin Oncol. 2009;27(28):4754-9.
56. Ross DM, Branford S, Moore S, Hughes TP. Limited clinical value of
regular bone marrow cytogenetic analysis in imatinib-treated chronic
phase CML patients monitored by RQ-PCR for BCR-ABL. Leukemia.
2006;20(4):664-70.
57. Press RD, Galderisi C, Yang R, Rempfer C, Willis SG, Mauro MJ, et al.
A half-log increase in BCR-ABL RNA predicts a higher risk of relapse
in patients with chronic myeloid leukemia with an imatinib-induced
complete cytogenetic response. Clin Cancer Res. 2007;13(20):6136-43.
58. Lange T, Bumm T, Otto S, Al-Ali HK, Kovacs I, Krug D, et al.
Quantitative reverse transcription polymerase chain reaction should not
replace conventional cytogenetics for monitoring patients with chronic
myeloid leukemia during early phase of imatinib therapy. Haematologica.
2004;89(1):49-57. Comment in: Haematologica
.
2004; 89(1):6-9.
59. Lima L, Bernal-Mizrachi L, Saxe D, Mann KP, Tighiouart M, Arellano
M, et al. Peripheral blood monitoring of chronic myeloid leukemia
during treatment with imatinib, second-line agents, and beyond. Cancer.
2011;117(6):1245-52.
60. Kantarjian H, Pasquini R, Hamerschlak N, Rousselot P, Holowiecki J,
Jootar S, et al. Dasatinib or high-dose imatinib for chronic-phase chronic
myeloid leukemia after failure of first-line imatinib: a randomized phase
2 trial. Blood. 2007;109(12):5143-50.
61. Kantarjian H, Pasquini R, Lévy V, Jootar S, Holowiecki J, Hamerschlak
N, et al. Dasatinib or high-dose imatinib for chronic-phase chronic
myeloid leukemia resistant to imatinib at a dose of 400 to 600 milligrams
daily: two-year follow-up of a randomized phase 2 study (START-R).
Cancer. 2009;115(18):4136-47.
62. Shah NP, Kantarjian HM, Kim DW, Réa D, Dorlhiac-Llacer PE,
Milone JH, et al. Intermittent target inhibition with dasatinib 100 mg
once daily preserves efficacy and improves tolerability in imatinib-
resistant and-intolerant chronic-phase chronic myeloid leukemia. J
ClinOncol. 2008;26(19):3204-12. Comment in: Nat Clin Pract Oncol.
2009;6(2):68-9.